ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 116 filers reported holding ALX ONCOLOGY HLDGS INC in Q3 2021. The put-call ratio across all filers is 0.35 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,780,800 | -36.1% | 2,871,000 | 0.0% | 0.29% | -25.1% |
| Q2 2023 | $21,561,210 | +66.2% | 2,871,000 | 0.0% | 0.39% | +53.3% |
| Q1 2023 | $12,976,920 | -59.9% | 2,871,000 | 0.0% | 0.26% | -58.8% |
| Q4 2022 | $32,356,170 | +17.8% | 2,871,000 | 0.0% | 0.62% | +21.4% |
| Q3 2022 | $27,475,000 | +55.3% | 2,871,000 | +31.3% | 0.51% | +59.4% |
| Q2 2022 | $17,687,000 | +68.3% | 2,186,269 | +251.7% | 0.32% | +88.2% |
| Q1 2022 | $10,507,000 | +135.5% | 621,700 | +199.5% | 0.17% | +198.2% |
| Q4 2021 | $4,461,000 | -59.7% | 207,600 | +38.4% | 0.06% | -53.3% |
| Q3 2021 | $11,079,000 | +35.1% | 150,000 | 0.0% | 0.12% | +47.0% |
| Q2 2021 | $8,202,000 | -25.8% | 150,000 | 0.0% | 0.08% | -19.4% |
| Q1 2021 | $11,061,000 | -14.5% | 150,000 | 0.0% | 0.10% | -8.8% |
| Q4 2020 | $12,930,000 | – | 150,000 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $163,929,000 | 36.34% |
| Logos Global Management LP | 3,011,352 | $50,892,000 | 6.60% |
| Vivo Capital, LLC | 4,220,048 | $71,319,000 | 4.91% |
| Samsara BioCapital, LLC | 262,786 | $4,441,000 | 1.12% |
| Cormorant Asset Management, LP | 712,079 | $12,034,000 | 0.92% |
| Pier Capital, LLC | 394,443 | $6,666,000 | 0.85% |
| Redmile Group, LLC | 772,397 | $13,054,000 | 0.41% |
| Artal Group S.A. | 500,000 | $8,450,000 | 0.35% |
| Nan Fung Group Holdings Ltd | 41,950 | $709,000 | 0.34% |
| Orbimed Advisors | 621,700 | $10,507,000 | 0.17% |